652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

医学 克拉斯 内科学 肿瘤科 不利影响 腺癌 恶心 皮疹 癌症研究 胃肠病学 癌症 结直肠癌
作者
Kathryn C. Arbour,Salman R. Punekar,Ignacio Garrido‐Laguna,David S. Hong,Brian M. Wolpin,Meredith S. Pelster,M. Barve,Alexander Starodub,D. Sommerhalder,Sam S. Chang,Y. Zhang,Zeena Salman,X. Wang,Corinne E. Gustafson,Alexander I. Spira
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S458-S458 被引量:26
标识
DOI:10.1016/j.annonc.2023.09.1838
摘要

RMC-6236 is a novel, oral RASMULTI(ON) inhibitor that is selective for the active, GTP-bound state of both mutant and wild-type variants of the canonical RAS isoforms. Preclinical studies have demonstrated deep and sustained regressions across multiple RASMUT tumor types, particularly PDAC and NSCLC harboring KRAS glycine-12 substitutions (KRASG12X). Patients with previously treated, advanced KRASG12X mutant solid tumors were enrolled at escalating doses (10mg to 160mg once daily (QD)) of single agent RMC-6236. Additional patients with PDAC or NSCLC were enrolled at dose levels that cleared dose-limiting toxicity evaluation. As of April 24, 2023, 22 patients with KRASG12X PDAC (13 G12D, 7 G12V, 2 G12R) and 11 with KRASG12X NSCLC (5 G12D, 4 G12V, 2 G12A) were enrolled, and 14 patients with PDAC and 9 patients with NSCLC continue treatment with RMC-6236. Median prior therapies was 3 (range, 1-7). Treatment-related adverse events (TRAEs) occurring in ≥10% of patients were rash (52%), diarrhea (21%), nausea (21%), and vomiting (15%). The only Grade ≥3 TRAE was in a patient with PDAC who had a Grade 4 large intestine perforation at the site of an invasive tumor that reduced in size on treatment. Preclinical modeling predicts tumor regressions at 80mg QD or higher in humans. Preliminary clinical activity in PDAC and NSCLC was assessed at 80mg and 120mg QD. Among 14 patients (10 PDAC, 4 NSCLC) dosed at least 8 weeks prior to the data cut-off date, the objective response rate was 36% (2 confirmed and 3 unconfirmed; 2/10 PDAC and 3/4 NSCLC). Median time to onset of initial response was 6 weeks (range, 5-11). Disease control rate was 86% (12/14; 8/10 PDAC and 4/4 NSCLC). Tumor reduction was observed in 4 patients with stable disease (range, -2% to -21% by RECIST v1.1). Of the 12 patients with partial response or stable disease, 11 continue on treatment. RMC-6236 exhibits promising anti-tumor activity in patients with KRASG12X PDAC and NSCLC at doses that are well tolerated. Dose escalation is ongoing and data from additional patients will be available at the time of the meeting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
震动的平松完成签到 ,获得积分10
2秒前
CooL完成签到 ,获得积分10
2秒前
luquanji完成签到,获得积分10
2秒前
朴实初夏完成签到 ,获得积分10
2秒前
5秒前
5秒前
niuya完成签到,获得积分10
6秒前
alvin完成签到,获得积分10
6秒前
6秒前
C_Li完成签到,获得积分10
7秒前
雪流星完成签到 ,获得积分10
8秒前
MchemG应助222采纳,获得10
9秒前
仙女蛋蛋打怪兽完成签到,获得积分10
10秒前
10秒前
青青完成签到 ,获得积分10
14秒前
15秒前
ET完成签到,获得积分10
16秒前
18秒前
从来都不会放弃zr完成签到,获得积分10
18秒前
Yxiang完成签到 ,获得积分10
18秒前
来了来了完成签到 ,获得积分10
19秒前
希望天下0贩的0应助djbj2022采纳,获得10
20秒前
司空天德发布了新的文献求助10
20秒前
Minguk完成签到,获得积分10
20秒前
yu_z完成签到 ,获得积分10
24秒前
krathhong完成签到 ,获得积分10
26秒前
可爱紫文完成签到 ,获得积分10
28秒前
丰富的大地完成签到,获得积分10
30秒前
沉甸甸完成签到,获得积分10
32秒前
pp完成签到 ,获得积分10
33秒前
依古比古完成签到,获得积分10
34秒前
你在教我做事啊完成签到 ,获得积分10
34秒前
jeffrey完成签到,获得积分10
35秒前
sdfdzhang完成签到 ,获得积分0
35秒前
兴奋的定帮完成签到 ,获得积分0
37秒前
LIKUN完成签到,获得积分10
40秒前
竹筏过海应助将军角弓采纳,获得30
40秒前
顾矜应助韭菜采纳,获得10
40秒前
43秒前
岁月如酒完成签到,获得积分10
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513393
关于积分的说明 11167478
捐赠科研通 3248836
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875131
科研通“疑难数据库(出版商)”最低求助积分说明 804664